B
29.57
0.32 (1.09%)
| Previous Close | 29.25 |
| Open | 29.73 |
| Volume | 462,798 |
| Avg. Volume (3M) | 761,193 |
| Market Cap | 1,301,808,384 |
| Price / Sales | 9.19 |
| Price / Book | 2.76 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | -101.62% |
| Operating Margin (TTM) | -105.69% |
| Diluted EPS (TTM) | -1.64 |
| Quarterly Revenue Growth (YOY) | 36.40% |
| Total Debt/Equity (MRQ) | 2.22% |
| Current Ratio (MRQ) | 15.88 |
| Operating Cash Flow (TTM) | -56.10 M |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Beta Bionics, Inc. | Bullish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 3.0 |
| Insider Activity | 1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 6.51% |
| % Held by Institutions | 98.41% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (Lake Street, 35.27%) | Buy |
| Median | 33.00 (11.60%) | |
| Low | 31.00 (Stifel, 4.84%) | Buy |
| Average | 34.33 (16.10%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 26.52 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Lake Street | 09 Jan 2026 | 40.00 (35.27%) | Buy | 20.14 |
| B of A Securities | 05 Jan 2026 | 33.00 (11.60%) | Buy | 29.57 |
| Truist Securities | 18 Dec 2025 | 37.00 (25.13%) | Buy | 29.06 |
| 29 Oct 2025 | 32.00 (8.22%) | Buy | 26.79 | |
| Goldman Sachs | 29 Oct 2025 | 33.00 (11.60%) | Buy | 26.79 |
| Piper Sandler | 29 Oct 2025 | 32.00 (8.22%) | Buy | 26.79 |
| Stifel | 29 Oct 2025 | 31.00 (4.84%) | Buy | 26.79 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CARNEY SEAN | 17.27 | - | 3,997 | 69,028 |
| DEAREN DANNY L. | 17.27 | - | 3,997 | 69,028 |
| JONES CHRISTY | 17.27 | - | 3,997 | 69,028 |
| LEZACK ADAM | 17.27 | - | 3,997 | 69,028 |
| MICHEL GERARD J | 17.27 | - | 3,997 | 69,028 |
| PALASIS MARIA | 17.27 | - | 3,997 | 69,028 |
| Aggregate Net Quantity | 23,982 | |||
| Aggregate Net Value ($) | 414,169 | |||
| Aggregate Avg. Buy ($) | 17.27 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DEAREN DANNY L. | Director | 13 Jan 2026 | Acquired (+) | 3,997 | 17.27 | 69,028 |
| JONES CHRISTY | Director | 13 Jan 2026 | Acquired (+) | 3,997 | 17.27 | 69,028 |
| LEZACK ADAM | Director | 13 Jan 2026 | Acquired (+) | 3,997 | 17.27 | 69,028 |
| CARNEY SEAN | Director | 13 Jan 2026 | Acquired (+) | 3,997 | 17.27 | 69,028 |
| PALASIS MARIA | Director | 13 Jan 2026 | Acquired (+) | 3,997 | 17.27 | 69,028 |
| MICHEL GERARD J | Director | 13 Jan 2026 | Acquired (+) | 3,997 | 17.27 | 69,028 |
| Date | Type | Details |
|---|---|---|
| 15 Jan 2026 | Announcement | Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 |
| 08 Jan 2026 | Announcement | Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics |
| 08 Dec 2025 | Announcement | Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026 |
| 03 Nov 2025 | Announcement | Beta Bionics Announces Participation at Upcoming Investor Conferences |
| 28 Oct 2025 | Announcement | Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |